The objectives of the study are to evaluate the efficacy, safety, and tolerability of AVP-923 compared to placebo for the treatment of bulbar dysfunction in patients with ALS.
The objective of the study is to evaluate the safety and efficacy of AVP-825 compared to placebo in the acute treatment of migraine in adolescent patients, 12 through 17 years-of-age.
The objectives of the studies are to evaluate the efficacy, safety, and tolerability of AVP-786 compared to placebo, for the treatment of agitation in patients with dementia of the Alzheimer’s type.
The objectives of this study are to evaluate the efficacy, safety, and tolerability of AVP-786 as an adjunctive treatment compared with placebo in patients with residual schizophrenia on negative and positive symptoms and cognitive function.
The objectives of the study are to evaluate the safety, tolerability, and efficacy of AVP-786 compared to placebo, for the treatment of disinhibition in patients with Neurodegenerative Disorders (NDD) including frontotemporal dementia, Alzheimer’s disease, progressive supranuclear palsy, corticobasal degeneration, dementia with Lewy bodies, vascular cognitive disorders, or Huntington’s disease.
The objectives of the study are to evaluate the efficacy, safety, and tolerability of AVP-786 compared to placebo, for the treatment of neurobehavioral disinhibition such as aggression, agitation, and irritability in patients with traumatic brain injury.
Medical Director, Clinical Development
Aliso Viejo, CA
The Medical Director, Clinical Development is responsible for the design, planning and medical oversight of clinical studies for all phases of development …
Neuroscience Area Manager, Long Term Care
Senior Clinical Research Associate
Aliso Viejo, CA
The Senior Clinical Research Associate will be responsible for initiation, monitoring and other tasks associated with the study management of clinical studies …
Senior Manager, Market Research
Aliso Viejo, CA
As a key leader in the Company’s finance organization, the Corporate Controller is responsible for managing the Company’s Accounting function …
Field Sales Trainer-LTC
Unlock the future of CNS treatment
Join our team of Innovators
Avanir employees are a diverse team of dedicated, accomplished professionals united by a common purpose: striving to make a change by developing innovative treatments for central nervous system (CNS) conditions.
Always moving Forward
Stay up to Date
Access to what’s happening at Avanir now, including stories, resources and information about our products, people and company.
We stand proudly by our commitment to research and development of treatments for CNS disorders and our relationships with advocacy organizations in our overarching commitment to help and support these patients and care communities. Our donations and support assist these organizations in
PBA is a neurological condition that affects up to an estimated 2 million Americans, but can be misunderstood by patients and their families. When someone with PBA has an intense laughing or crying episode, he or she can feel powerless, embarrassed, or discomforted. PBA occurs in people who already
In this interview with Modern Counsel magazine, Avanir VP and General Counsel Garlan Adams shares her thoughts on how the biotechnology and pharmaceutical industry is transforming disease treatment. Based on her 18 years of industry experience, Garlan describes the challenges of the drug
A portion of our activities dedicated to reducing bias among the general public about nerve and mental diseases has won the Bronze for the Pharma category of Lions Health at the 63rd Cannes Lions International Festival of Creativity, the most prestigious international award for creativity. The